Press Release for Signing of Grant Agreement for “Observational Study on COVID-19 Vaccine Immunogenicity and Reactogenicity in Bhutan”
A grant agreement for the “Observational Study on COVID-19 Vaccine Immunogenicity and Reactogenicity in Bhutan” was signed by the Secretary of the Gross National Happiness Commission, the Director of Bhutan Foundation, and the President of Khesar Gyalpo University of Medical Sciences of Bhutan (KGUMSB) on February 15, 2022.
The goal of the project is to conduct a study on reactogenicity and immunogenicity of homologous (AstraZeneca-AstraZeneca) and heterologous (AstraZeneca-Moderna) booster vaccines in adults, the efficacy of homologous (Moderna-Moderna) vaccines in children (12-17 years old), and vaccine breakthroughs in Bhutan. This project will strengthen laboratory and research capacity to conduct high-quality vaccine research studies in Bhutan. The study will help the Royal Government of Bhutan to conduct virological surveillance, make policy decisions, and develop strategies to combat COVID-19 as well as other epidemiological strategies.
The USD 3.3 million project is supported by Moderna Inc in partnership with the Bhutan Foundation. It will be implemented by KGUMSB in collaboration with the Ministry of Health.